Clinical Trial

Study of IMC-S118AI in Type 1 Diabetes

Name: Study of IMC-S118AI in Type 1 Diabetes — clinical trial record (NCT07493122)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.

Trial Details

NCT Number	NCT07493122
Lead Sponsor	Immunocore Ltd
Conditions	Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1
Enrollment	154 participants
Start Date	2026-04
Primary Completion	2030-11 (estimated)
Study Completion	2030-11 (estimated)
Updated on ClinicalTrials.gov	2026-03-25